Cardiovascular Systems, Inc. to Post Q1 2023 Earnings of ($0.22) Per Share, Zacks Research Forecasts (NASDAQ:CSII)
Cardiovascular Systems, Inc. to Post Q1 2023 Earnings of ($0.22) Per Share, Zacks Research Forecasts (NASDAQ:CSII)
Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating) – Zacks Research issued their Q1 2023 earnings per share (EPS) estimates for Cardiovascular Systems in a research report issued on Wednesday, September 28th. Zacks Research analyst D. Dey anticipates that the medical device company will post earnings of ($0.22) per share for the quarter. The consensus estimate for Cardiovascular Systems' current full-year earnings is ($0.67) per share. Zacks Research also issued estimates for Cardiovascular Systems' Q2 2023 earnings at ($0.16) EPS, Q3 2023 earnings at ($0.15) EPS, Q4 2023 earnings at ($0.15) EPS, FY2023 earnings at ($0.68) EPS, Q1 2024 earnings at ($0.18) EPS, Q2 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.53) EPS and FY2025 earnings at ($0.49) EPS.
心血管系统公司(纳斯达克代码：CSII-GET Rating)-扎克斯研究公司在9月28日星期三发布的一份研究报告中发布了他们对心血管系统2023年第一季度每股收益的估计。扎克斯研究公司的分析师D.Dey预计，这家医疗设备公司本季度的每股收益将达到0.22美元。对心血管系统公司目前全年收益的普遍估计是每股0.67美元。扎克斯研究公司还发布了对心血管系统公司2023年第二季度每股收益(0.16美元)、2023年第三季度每股收益(0.15美元)、2023年第四季度每股收益(0.15美元)、2023年第四季度每股收益(0.68美元)、2024年第一季度每股收益(0.18美元)、2024年第二季度每股收益(0.11美元)、2024年第三季度每股收益(0.18美元)、2024年第四季度每股收益(0.07美元)、2024年第四季度每股收益(0.53美元)和2025财年每股收益(0.49美元)的预测。
Cardiovascular Systems Trading Down 1.1 %
心血管系统降价1.1%
Shares of CSII stock opened at $13.86 on Monday. The company has a quick ratio of 5.19, a current ratio of 6.05 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average price of $14.72 and a two-hundred day moving average price of $16.46. Cardiovascular Systems has a 12-month low of $12.51 and a 12-month high of $36.97. The firm has a market cap of $567.77 million, a P/E ratio of -14.59 and a beta of 0.97.
CSII股票周一开盘报13.86美元。该公司的速动比率为5.19，流动比率为6.05，债务权益比率为0.08。该业务的50日移动均线价格为14.72美元，200日移动均线价格为16.46美元。心血管系统公司的12个月低点为12.51美元，12个月高位为36.97美元。该公司市值为5.6777亿美元，市盈率为-14.59倍，贝塔系数为0.97。
Institutional Investors Weigh In On Cardiovascular Systems
机构投资者参与心血管系统
Several hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its stake in Cardiovascular Systems by 0.6% during the fourth quarter. Rhumbline Advisers now owns 99,634 shares of the medical device company's stock worth $1,871,000 after purchasing an additional 566 shares during the last quarter. UBS Group AG lifted its stake in shares of Cardiovascular Systems by 6.3% in the 2nd quarter. UBS Group AG now owns 11,500 shares of the medical device company's stock valued at $165,000 after acquiring an additional 679 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Cardiovascular Systems by 32.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,025 shares of the medical device company's stock valued at $68,000 after acquiring an additional 735 shares during the last quarter. Eaton Vance Management lifted its stake in shares of Cardiovascular Systems by 5.4% in the 4th quarter. Eaton Vance Management now owns 14,547 shares of the medical device company's stock valued at $252,000 after acquiring an additional 749 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its stake in shares of Cardiovascular Systems by 3.1% in the 2nd quarter. Perkins Capital Management Inc. now owns 25,200 shares of the medical device company's stock valued at $362,000 after acquiring an additional 750 shares during the last quarter. Institutional investors own 91.72% of the company's stock.
几家对冲基金最近增持或减持了该公司的股份。Rhumbline Advisers在第四季度将其在心血管系统公司的股份增加了0.6%。Rhumbline Advisers现在拥有这家医疗设备公司99,634股股票，价值1,871,000美元，上个季度又购买了566股。瑞银集团(UBS Group AG)第二季度增持了6.3%的心血管系统股票。瑞银集团(UBS Group AG)现在持有这家医疗设备公司11,500股股票，价值16.5万美元，上个季度又购入了679股。PNC金融服务集团(PNC Financial Services Group Inc.)在第一季度增持了32.1%的心血管系统股票。PNC金融服务集团(PNC Financial Services Group Inc.)在上个季度增持了735股后，现在持有这家医疗设备公司3,025股股票，价值6.8万美元。伊顿·万斯管理公司在第四季度增持了心血管系统公司5.4%的股份。在上个季度增持了749股后，伊顿·万斯管理公司现在持有这家医疗器械公司14,547股股票，价值252,000美元。最后，珀金斯资本管理公司(Perkins Capital Management Inc.)在第二季度增持了心血管系统股份3.1%。珀金斯资本管理公司(Perkins Capital Management Inc.)在上个季度增持了750股后，现在持有这家医疗设备公司25,200股，价值36.2万美元。机构投资者持有该公司91.72%的股票。
Cardiovascular Systems Company Profile
心血管系统公司简介
(Get Rating)
(获取评级)
Cardiovascular Systems, Inc, a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.
心血管系统公司是一家医疗技术公司，在美国和国际上开发和销售治疗外周和冠状动脉疾病的解决方案。该公司提供外周动脉疾病产品，包括基于导管的平台，用于治疗膝盖以上和膝盖以下的各种斑块类型，包括钙化斑块，以及解决与手术、导管和药物治疗替代方案相关的各种限制；以及外周支持产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Cardiovascular Systems (CSII)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免费获取StockNews.com心血管系统研究报告(CSII)
- 阿彻·丹尼尔斯·米德兰：49年增长的红利英雄
- 全自动拖拉机会让迪尔成为农业领域的特斯拉吗？
- 麦格纳国际是您的汽车和电动汽车一站式库存
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.
接受《每日心血管系统》新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对心血管系统和相关公司的最新新闻和分析师评级的每日简要摘要。